๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

181 results for โ€œanti-โ€ Clear

  1. Sodio cloruro S.A.L.F. 0,9% solvente per uso parenterale., BCG 10 Anti-Tuberculosis Vaccine, Powder and solvent for suspension for intradermal injection Vaccinum tuberculosis (BCG) cryodesiccatum

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  2. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naรฏve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  3. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  4. Tarperprumig Placebo, Tarperprumig

    Alexion Europe SAS

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial

  5. TransCon TLR7/8 Agonist, TransCon IL-2 รŸ/าฏ, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  6. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  7. anti-BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  8. anti-BCMA-CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 mab active

    2 trials

  9. anti-BCMA/CD3 bispecific antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. anti-CD133-CAR vector-transduced T cells

    Chinese PLA General Hospital

    Liver Cancer

    phase 2 mab completed

    1 trial

  11. anti-CD7 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  12. anti-FLT3 CAR-T

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  13. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  14. anti-MUC1 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  15. anti-thymocyte globulin

    Ultragenyx UK Limited

    Fanconi's Anemia

    phase 2 small molecule completed

    1 trial

  16. anti-thymocyte globulin

    Ultragenyx UK Limited

    Systemic Sclerosis

    phase 2 small molecule completed

    1 trial

  17. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  18. neoadjuvant anti-PD-1

    Shanghai Chest Hospital

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  19. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  20. remicade (anti tumor necrosis factor inhibitor)

    Hospital Authority, Hong Kong

    Takayasu's Arteritis

    phase 2 small molecule active

    1 trial

  21. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  22. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  23. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRฮฑ) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources